Keywords: Alloss Thera, Mundipharma, Folotyn, Blood cancer, Lymphoma

Allos Therapeutics and Mundipharma ink $360 million deal for Folotyn

Article | 13 May 2011

USA-based Allos Therapeutics (Nasdaq: ALTH) and privately-held Mundipharma International have entered into a strategic collaboration to co-develop Folotyn (pralatrexate injection). ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Mundipharma

Allos Therapeutics

Go to company listing

Related Drugs

Folotyn

Go to drug listing